StockNews.AI
CDXS
StockNews.AI
187 days

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

1. Codexis will report Q4 2024 financial results on February 27, 2025. 2. A conference call will follow for discussion of the business update. 3. Codexis leverages proprietary technology to enhance enzyme efficiency. 4. Their ECO Synthesis platform aims for RNAi therapeutics manufacturing. 5. Improvements include higher yields and reduced energy usage.

Earnings
+5.12%Current Return
VS
0%S&P 500
$4.102/13 04:07 PM EDTEvent Start
$4.3102/14 10:44 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

Earnings announcements often lead to positive market reactions, especially if results exceed expectations.

How important is it?

The upcoming earnings report could significantly affect investor sentiment toward CDXS.

Why Short Term?

Immediate reactions to earnings calls can impact stock price quickly, though sustainability is uncertain.

Related Companies

CDXSBMYMRK
February 13, 2025 16:05 ET  | Source: Codexis, Inc. REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the fourth quarter and fiscal year 2024 on Thursday, February 27, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635. About CodexisCodexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com. For More Information Investor ContactCarrie McKim(336) 608-9706ir@codexis.com Media ContactLauren Musto(650) 421-8205media@codexis.com

Related News